Overview
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), often combined with ipamorelin in online protocols. A version with 'DAC' (drug affinity complex) is designed to extend its half-life.
How It's Thought to Work
As a GHRH analog, it stimulates the pituitary to release growth hormone, which can raise IGF-1 levels.
What the Research Says
Some early human pharmacology studies exist on GH/IGF-1 elevation; long-term clinical outcome data is limited.
Regulatory & Legal Status
Not approved by the FDA for human use. Sold as a research chemical. Prohibited in sport by WADA.
Safety Considerations
Limited human safety data; unregulated purity. Consult a qualified clinician.